EFB Dengue Literature Review

Double-Negative B Cell

40 min read

Double-Negative B Cell

Overview

This page is the canonical entry for the IgD⁻CD27⁻ (double-negative) population specifically. For the broader atypical / age-associated B cell umbrella — the synonymy map across the “atypical,” “ABC,” “T-bet⁺,” “CD11c⁺,” and “alternative lineage” labels, and how they route to the precise DN sub-populations — see Atypical B Cell.

Double-negative (DN) B cells are a peripheral blood memory B cell subset defined by the co-absence of surface IgD and CD27 (IgD⁻CD27⁻ CD19⁺). They are distinct from both conventional CD27⁺ memory B cells (switched and unswitched) and from naive B cells (IgD⁺CD27⁻). Despite lacking CD27 — long considered a universal memory B cell marker — DN B cells carry hallmarks of antigen-experienced memory: somatic hypermutation of VH genes, inability to extrude Rhodamine 123, and proliferative responses to TLR9 stimulation (CpG DNA) without BCR crosslinking.

In healthy peripheral blood, DN B cells are a minor population (~5% of CD19⁺ B cells). They are substantially expanded in systemic lupus erythematosus (SLE) and, by extension, serve as the foundational reference population for the “atypical B cell” or “T-bet⁺ B cell” expansions subsequently described in infection — in this wiki’s ingested corpus: malaria (Sutton2021 - Alternative Lineage B Cells in Vaccination and Infection), SARS-CoV-2 (Woodruff2020 - EF B Cell Responses in COVID-19, Kaneko2020 - GC Loss and TFH Block in COVID-19), and — of primary interest here — dengue (Ansari2025 - Peripheral T Helper Subset Drives B Cell Response in Dengue, Singh2026 - DENV-Specific Memory B Cell Subsets).

Ebola was previously listed here without attribution and has been removed [2026-08-18]: no ingested source in this wiki reports DN/atypical B cell data in Ebola. CLAUDE.md Domain Context names Ebola as an intended comparative benchmark, so this is an evidence gap, not a scope change.

DN1/DN2/DN3 subdivision: Jenks et al. (2018) resolved the DN compartment into two functionally distinct subsets: DN1 (CXCR5⁺, CD21⁺, CD11c^lo) and DN2 (CXCR5⁻, CD21⁻, CD11c⁺, CD19^hi). DN1 cells predominate in healthy donors and transcriptionally resemble switched memory cells (only 22 DEGs by RNA-seq); DN2 cells predominate in active SLE and represent extrafollicular pre-plasmablasts. These subsets belong in separate differentiation pathways — DN1 are likely early SWM precursors that have not yet acquired CD27, while DN2 are effector cells derived from activated naive B cells via the EF pathway. A third subset, DN3 (CXCR5⁻, CD21⁻, CD11c⁻, T-bet⁻), was subsequently described in acute COVID-19 and active SLE, representing pre-plasmablasts distinct from both DN2 and ABC (see DN3 B Cell). See DN2 B Cell for the full DN2 characterisation.

A four-subset scheme (DN1–DN4): One lineage of the literature (largely the Sachinidis/Garyfallos group, building on Somers 2022 / Castleman 2022) extends the DN compartment to four subsets classified by CXCR5 / CD11c / T-bet: DN1 (CXCR5⁺CD11c⁻T-bet⁻), DN2 (CXCR5⁻CD11c⁺T-bet⁺), DN3 (CXCR5⁻CD11c⁻T-bet^low), and DN4 (CXCR5⁺CD11c⁻T-bet⁻). DN1 and DN4 are CXCR5⁺ (follicle-competent) whereas DN2 and DN3 are CXCR5⁻ and are the subsets most tied to extrafollicular responses and autoimmunity. DN4 is the least-defined subset: associated with allergic reactions, expressing Notch-signalling and protein-ubiquitination genes that distinguish it from DN1 (Allard-Chamard 2023). The wiki’s default remains the three-subset DN1/DN2/DN3 scheme (after Sanz2025); the DN4 designation is noted here as nomenclature drift rather than an independently validated fourth lineage (see Lamprinou2026 - ABCs and DN B Cells, opinion; and Atypical B Cell Contradictions).

⚠★ [2026-08-27] The DN4 marker definition above conflicts with the primary, and the wiki does not resolve it. The primary that originated the DN1–DN4 scheme, Allard-Chamard2023 - DN3 B Cells Infiltrate Inflamed Tissues, gates the DN compartment as a CXCR5 × CD11c quadrant with no CD21 and no T-bet in the panel: DN1 = CXCR5⁺CD11c⁻, DN2 = CXCR5⁻CD11c⁺, DN3 = CXCR5⁻CD11c⁻, DN4 = CXCR5⁺CD11c⁺ (Fig. 1B and 1C quadrant labels, independently confirmed by the tissue marker-validation panel Fig. 6C). The Lamprinou relay above records DN4 as CXCR5⁺CD11c⁻ — which is DN1’s phenotype, making the two subsets indistinguishable. Both positions are recorded per Rule 4. The primary’s gate is the directly observed one and is what any reproduction attempt should follow; the standing [2026-08-16] PDF-only rule bars fetching Szelinski 2022 / Sachinidis / Castleman 2022 to break the tie, so this stays open. Tracked as a Watch Item.

DN4 — what the primary actually reports

Kept as a section here rather than a standalone page (curator decision, 2026-08-27): the evidence base is one n=4 transcriptome plus small tissue counts, too thin for its own page, and the wiki’s standing “nomenclature drift” position is unchanged. From Allard-Chamard2023 - DN3 B Cells Infiltrate Inflamed Tissues (n=38 blood, n=4 RNA-seq, n=6–10 tissue):

  • Phenotype: IgD⁻CD27⁻CXCR5⁺CD11c⁺ — the only DN subset positive for both axes. Being CXCR5⁺ it is follicle-competent; being CD11c⁺ it carries the ABC/DN2 marker. This combination is what makes it awkward for the EF framing, and may be why it has attracted so little follow-up.
  • A small population, distinguished from DN1 by Notch signalling and protein ubiquitination gene sets (n=4 bulk RNA-seq).
  • SLAMF7 MFI 956 — the second-lowest of the four subsets (DN2 2123 > DN3 1536 > DN4 956 > DN1 895).
  • Blood, IgG4-RD (n=38): significantly increased as % of total B cells (p<0.05), but the smallest subset in absolute terms (axis to ~3% of B cells vs ~15% for DN3). Correlation with plasmablast frequency r = 0.4037, p = 0.0662 — not significant. Logistic regression OR 18.7 (95% CI 1.745–200.97), p = 0.0155 — significant, but with an interval spanning two orders of magnitude.
  • Tissue: ~19 vs ~0.5 cells/mm² in IgG4-RD salivary gland vs chronic sialadenitis; ~5.5 vs ~0 cells/mm² in COVID-19 vs control lung; ~17 cells/mm² in COVID-19 thoracic lymph node. As a share of the lung DN pool, DN4 was ~26% in COVID-19 vs ~10% in control — the largest proportional shift of any DN subset in that comparison, though no significance markers are printed on the subset-level panels.
  • Verdict unchanged: interesting, under-replicated, and defined by a single group. The wiki continues to default to DN1/DN2/DN3.

The “atypical B cell” label is obsolete: Sanz (2025) argues that the term AtB is misleading because: (1) cells thus labelled are a normal component of immune responses, not atypical; (2) the actual nature, derivation, and function of different AtB categories depend on the immunological context; (3) inconsistent classification schemes (CD27⁻, CD21lo, CD11c⁺, T-bet⁺, FcRL5⁺ — used alone or in combinations, often without IgD) conflate fundamentally different populations. The DN nomenclature (IgD⁻CD27⁻, subdivided by CXCR5/CD21/CD11c into DN1, DN2, DN3) is recommended as the more precise classification (see Sanz2025 - Human Atypical B Cells Overview, invited review).

Key Points from Literature

  • DN B cells represent mean 4.6 ± 1.8% of PBL CD19⁺ B cells in healthy subjects (n=29), always below 10% (see Wei2007 - DN Memory B Cells in SLE, n=29 cross-sectional).

  • In SLE, DN cells exceed 10% of CD19⁺ PBL B cells in 50% of patients (mean 19.4% in DN-high subgroup; up to >40% in individual patients); in 25% of SLE patients they outnumber CD27⁺ memory cells (see Wei2007 - DN Memory B Cells in SLE, n=36 SLE cross-sectional).

  • DN expansion is SLE-specific: not elevated in rheumatoid arthritis (n=45) or chronic hepatitis C (n=7) (see Wei2007 - DN Memory B Cells in SLE, cross-sectional).

  • Somatic hypermutation: IgG⁺ DN cells carry ~3.2% nucleotide mutation rate in healthy donors and ~2.6% in SLE; CD27⁺ IgG⁺ memory cells carry ~5.4% (healthy) and ~5.1% (SLE). DN cells are thus antigen-experienced but less mutated than their CD27⁺ counterparts (see Wei2007 - DN Memory B Cells in SLE, VH3 family analysis).

  • Isotype composition: ~44% IgG⁺, ~15% IgM⁺ in healthy DN cells; DN IgM⁺ cells notably lack IgD co-expression, unlike the majority of CD27⁺ nonswitched memory cells (see Wei2007 - DN Memory B Cells in SLE, cross-sectional).

  • DN cells fail to extrude Rhodamine 123 (identical to CD27⁺ memory cells; naive B cells extrude it), attributable to absence of ABCB1 transporter (see Wei2007 - DN Memory B Cells in SLE, in vitro functional assay).

  • DN cells proliferate in response to CpG2006 without BCR crosslinking; naive B cells require BCR co-stimulation. Proliferating DN cells upregulate CD27 (see Wei2007 - DN Memory B Cells in SLE, in vitro functional assay).

  • FcRH4 expression: Peripheral blood DN cells are FcRH4⁻ (both healthy and SLE), distinguishing them from a tissue-resident tonsillar CD27⁻ population that expresses FcRH4 (see Wei2007 - DN Memory B Cells in SLE, cross-sectional; see also FcRH4).

  • CD38 level: DN cells express CD38 at Bm5/early-Bm5 levels — below pre-GC cells, transitional cells, and plasmablasts (see Wei2007 - DN Memory B Cells in SLE).

  • Surface phenotype (CD24, IgM, CD10, B220) is virtually identical between DN cells and conventional CD27⁺ switched memory cells; both populations lack CD10, distinguishing them from transitional and pre-GC B cells (see Wei2007 - DN Memory B Cells in SLE, 8-color flow cytometry).

  • Tonsil counterpart: the IgD⁻CD27⁻CD10⁻ fraction of Bm5 cells; contains both FcRH4⁺ and FcRH4⁻ subsets, unlike PBL DN cells which are uniformly FcRH4⁻ (see Wei2007 - DN Memory B Cells in SLE).

  • Clinical association in SLE: DN-high patients (>10%) have higher nephritis rates (p=0.025), anti-dsDNA (p=0.001), anti-RNP/Sm (p=0.009), SLAM disease activity (p=0.02), and elevated 9G4 autoreactive B cells (see Wei2007 - DN Memory B Cells in SLE, n=46 SLE patients).

  • 9G4 autoreactive B cells (encoded by VH4-34) are present at similar frequencies within the DN and CD27⁺ switched memory compartments of individual SLE patients — suggesting autoreactive specificities are not excluded from the DN compartment (see Wei2007 - DN Memory B Cells in SLE).

  • Independent cohort replication of DN expansion: In a separate clinical cohort (n=8 SLE, n=7 controls), DN cells were 14.4 ± 7.9% of CD19⁺ PBL B cells in SLE vs. 3.9 ± 1.9% in controls (P=0.01) — corroborating the Wei2007 frequency estimates with a matched control comparison (see Anolik2004 - Rituximab and B Cell Abnormalities in SLE, phase I/II trial).

  • Quantitative correlation with autoantibody titers: DN expansion correlates with VH4.34 IgG autoreactive antibody levels (R²=0.8, P<0.05) — a stronger correlation than that seen for naive lymphopenia (R²=0.6 for VH4.34). This positions DN expansion as the closer correlate of autoreactive B cell biology (see Anolik2004 - Rituximab and B Cell Abnormalities in SLE).

  • Reversibility after B cell depletion: After effective rituximab-mediated B cell depletion and immune reconstitution (≥1 year), DN expansion resolved significantly (P=0.05 vs. baseline) in patients with effective depletion. Patients with incomplete depletion did not show resolution. This demonstrates that DN accumulation is driven by ongoing B cell dysregulation, not irreversible programming (see Anolik2004 - Rituximab and B Cell Abnormalities in SLE).

  • DN compartment composition in severe COVID-19 mirrors active SLE: In critically ill COVID-19 patients (CoV-A cluster), DN composition was skewed heavily toward DN2 (80.3% of DN cells in a representative ICU patient vs. 9.5% in HD). DN1 contracted correspondingly (9.8% vs. 68.0% in HD). DN3 cells were also expanded (8.5% in ICU vs. 15.1% in HD). The overall DN compartment was greatly expanded (19.3% of CD19⁺ B cells in ICU vs. 3.0% in HD). Direct comparison showed DN profiles in CoV-A were highly similar to active SLE — both showed strong DN2 skewing with concordant DN1 contraction (see Woodruff2020 - EF B Cell Responses in COVID-19, 24-marker spectral FCM, n=10 ICU-C, n=7 OUT-C, n=17 HD, n=7 SLE).

  • DN2:DN1 ratio elevated in severe COVID-19 to SLE-comparable levels: log₂(DN2:DN1) ratios were significantly higher in both CoV-A and active SLE than in HD and CoV-B (P ≤ 0.0001 and P ≤ 0.001 respectively). DN2:DN1 ratio was not significantly different between CoV-A and SLE, confirming that the EF pathway achieves equivalent DN skewing in acute viral infection as in chronic autoimmunity (see Woodruff2020 - EF B Cell Responses in COVID-19).

  • Unswitched memory contraction accompanies DN2 expansion: usM cells were significantly reduced in CoV-A, a feature consistently observed in SLE and other autoimmune diseases. This suggests that EF pathway activation may come at the cost of the unswitched memory compartment (see Woodruff2020 - EF B Cell Responses in COVID-19).

  • FIRST DENGUE DATA — DENV-specific “atypical” (CD27⁻CD21⁻) MBCs accumulate in 2° dengue: DENV-specific atypical MBCs (CD20+/IgD⁻/CD27⁻/CD21⁻) — corresponding to DN B cells — were significantly higher in 2° than 1° dengue at early convalescence (p<0.01) and at 18 months (p<0.05), with a significant main effect of infection history across all timepoints (Two-way RM-ANOVA p<0.001). Resting MBCs (CD27+/CD21+) did not differ by infection history, indicating the DN/atypical compartment selectively expands with repeat DENV exposure. Temporal correlation analysis suggests DENV-specific atypical MBCs at acute/3M correlate with later class-switched and activated MBC levels in 2° immunity, implying functional responsiveness rather than exhaustion (see Singh2026 - DENV-Specific Memory B Cell Subsets, n=58 samples, 18 pediatric patients, conventional 12-color FCM).

  • Limitation — DN1/DN2/DN3 resolution not possible: The Singh2026 panel lacks CXCR5 and CD11c, so the DENV-specific “atypical” (CD27⁻/CD21⁻) population cannot be subdivided into DN1, DN2, or DN3. Per the Sanz2025 criterion, the expanded population could be EF-derived DN2 effectors, GC-derived DN1 memory, or a heterogeneous mix. The panel does include IgD, passing the Sanz2025 IgD audit (see Singh2026 - DENV-Specific Memory B Cell Subsets).

  • FIRST EVIDENCE OF CD21⁻CD11c⁺ EF B CELLS IN DENGUE: Within the IgD⁻CD27⁻ (DN) gate, CD21⁻CD11c⁺ B cells — phenotypically consistent with DN2 — are significantly expanded during acute dengue infection compared to healthy donors and convalescence. These cells are CD19^hi and CXCR5^lo (by inference from parallel T cell data). This is the first direct demonstration that the EF B cell phenotype characterised in SLE (Jenks2018) and COVID-19 (Woodruff2020) is also present in dengue (see Ansari2025 - Peripheral T Helper Subset Drives B Cell Response in Dengue, multi-color FCM, n=170 acute dengue).

  • EF B cell expansion driven by Tph-IL-21 axis: The CD21⁻CD11c⁺ B cell expansion occurs in the context of massive Tph (CXCR5⁻PD-1⁺) T cell activation providing IL-21. Blocking IL-21 reduces plasmablast output by ~60%. The Tph→IL-21→memory B cell→plasmablast axis represents the T cell help arm of EF activation in dengue (see Ansari2025 - Peripheral T Helper Subset Drives B Cell Response in Dengue).

  • TISSUE-LEVEL DN B CELLS IN COVID-19 — present at both follicular and extrafollicular sites: Post-mortem immunofluorescence of COVID-19 lymph nodes and spleens identified IgD⁻CD27⁻ DN B cells within and outside follicles, with T-B conjugates at both sites. Peripheral blood analysis using dual-fluorophore RBD probes confirmed that DN populations (DN2 and DN3 as CXCR5-low; DN1 and DN4 as CXCR5-high) contain SARS-CoV-2-specific cells, establishing that the DN expansion is antigen-driven. Switched memory cells were the largest RBD⁺ subset (53.6% convalescent, 39.1% severe) (see Kaneko2020 - GC Loss and TFH Block in COVID-19, tissue: n=11 COVID + controls, multi-color immunofluorescence; blood: n=68 patients, 13-color FCM).

  • CD21⁻CD27⁻ gating captures only 44.7% of transcriptomically-defined atypical B cells: CITE-seq (combined transcriptome + surface protein) on >12,000 B cells revealed that the conventional CD21⁻CD27⁻ flow cytometry gate captures fewer than half of the cells that cluster transcriptomically as atBC1 (the most prominent alternative lineage cluster). CD11c protein expression was a superior single marker for identifying the alternative lineage. This has major implications for all prior flow cytometry studies using the DN gate — including dengue studies — which likely underestimate the true size of this population (see Sutton2021 - Alternative Lineage B Cells in Vaccination and Infection, n=4, CITE-seq).

  • Alternative lineage present at ~20% of B cells in healthy non-exposed donors: Transcriptomic clustering identified alternative lineage cells (atBC1, atBC2, atBC3, MBC1) in non-malaria-exposed Australian donors at ~20% of total B cells — far above the ~5% typically reported for CD21⁻CD27⁻ DN cells by flow cytometry. The discrepancy is explained by the gating limitation above (see Sutton2021 - Alternative Lineage B Cells in Vaccination and Infection, n=4, 10x Chromium; validated by flow cytometry n=18).

  • MBC1 cluster — transcriptomic evidence for quiescent alternative lineage memory: The MBC1 cluster sits at the base of the alternative lineage pseudotime branch, expresses memory markers but lacks activation markers, and represents a quiescent memory state. This provides transcriptomic support for the “memory DN2” population predicted by Sanz2025 and Faliti2024 (see Sutton2021 - Alternative Lineage B Cells in Vaccination and Infection, n=4, 10x Chromium).

  • IgG3 overrepresented in alternative lineage in malaria-exposed donors: Alternative lineage B cells were enriched for IgG3 isotype compared to classical lineage cells in malaria-exposed Kenyan donors, consistent with the IgG3 enrichment on DN2 cells reported in SLE by Jenks2018 (see Sutton2021 - Alternative Lineage B Cells in Vaccination and Infection, n=4, 10x Chromium).

  • Only DN2 corresponds to the ABC/T-bet⁺ population — and only one ABC subset corresponds to DN. Among DN subsets, only DN2 highly expresses T-bet and CD11c and efficiently differentiates into plasma cells; DN1, DN3, and DN4 lack CD11c/T-bet and so fall outside the ABC definition. Conversely, ABC is a heterogeneous superset (CD27⁺ + IgD⁺ + predominantly IgD⁻CD27⁻ cells), so only its IgD⁻CD27⁻ fraction maps onto DN — CD27⁺ ABCs are excluded because DN is CD27⁻ by definition (see Lamprinou2026 - ABCs and DN B Cells, opinion, citing Jenks 2018 / Tangye 2023 / Rubtsov 2011). ABC and DN frequencies nonetheless correlate in both health and lupus (citing Sachinidis 2025 / Chizzolini 2024).

  • DN4 — a poorly defined, allergy-associated CXCR5⁺ subset. In the four-subset scheme, DN4 (CXCR5⁺CD11c⁻T-bet⁻) is allergy-associated and expresses Notch-signalling and protein-ubiquitination genes distinguishing it from DN1; being CXCR5⁺ and T-bet⁻, it is not an EF effector and not an ABC. Its evidence base is largely secondary/self-cited (see Lamprinou2026 - ABCs and DN B Cells, opinion, citing Somers 2022 / Castleman 2022 / Allard-Chamard 2023).

  • A cytoplasmic-FOXO1⁺ DN population in SLE awaits subset assignment. A DN B cell population marked by cytoplasmic FOXO1 (a TF central to B-cell development) has been described in SLE, but whether it corresponds to DN2, DN3, or a distinct subset is unknown (see Lamprinou2026 - ABCs and DN B Cells, opinion, citing Hritzo Ahye & Golding 2018).

  • ⚠★ FALSE FRIEND — a second, unrelated “DN B cell” exists in the murine memory literature, and it means the opposite kind of cell. The GC-fate-mapping and Shlomchik-lab memory literature subsets MBCs on CD80 and PD-L2, yielding DP (CD80⁺PD-L2⁺), SP (CD80⁻PD-L2⁺), and DN (CD80⁻PD-L2⁻). In that scheme DP is enriched for GC-derived MBCs and “DN” consists almost exclusively of GC-independent early MBCs — so “DN” is a proxy for developmental origin and has nothing to do with IgD or CD27 (see Glaros2025 - Multilayered Identity of B Cell Memory, review, citing mouse GC-specific fate mapping). Practical consequences when importing murine memory papers:

    • A “DN MBC” there is quiescent, low-SHM, largely unswitched IgM⁺, and biased toward secondary GC reentry — close to the inverse of this wiki’s activated CD21⁻CD11c⁺ DN2 effector.
    • Functional claims about “DN MBCs” from that literature (e.g. “DN MBCs more efficiently reenter secondary GCs”) must not be transplanted onto IgD⁻CD27⁻ DN cells.
    • The mapping is not even clean within its own scheme: a considerable proportion of DP cells originate from the non-GC pathway.
    • Where a paper’s DN definition is ambiguous, check whether IgD/CD27 or CD80/PD-L2 was used before citing it here. See the synonymy map on Atypical B Cell.

  • Cancro treats human DN cells as the ABC counterpart. The review describes “ABC-like cells termed double negative (DN)” (Ettinger and Sanz groups) as the human population corresponding to murine ABCs, noting that both TLR7 and IL-21 are key signals in the human DN differentiation programme, and that many unique transcriptional characteristics are shared between murine ABCs and human DN cells (see Cancro2020 - Age-Associated B Cells, review — no original data; human and mouse).

  • Wang et al. 2018: blood ABC/DN frequency correlates with SLEDAI and is highly enriched for autoantibody specificities. In a belimumab trial, loss of the ABC-phenotype population correlated with therapeutic response (see Cancro2020 - Age-Associated B Cells, review — no original data; human, clinical cohort).

  • Molecular basis of the Rhodamine 123 phenotype — DN cells are ABCB1-negative. The R123 retention that Wei2007 used as a memory credential is explained by absence of the ATP-binding-cassette-B1 transporter: DN cells are ABCB1⁻ in both aged HD and SLE patients, matching SM cells and contrasting with naive and unswitched memory cells (see Beckers2023 - Origins and Functions of DN B Cells, review, citing Colonna-Romano 2009 / Wei 2007 / Wirths 2005).

  • Replicative-history evidence: DN telomeres match switched memory, not naive. DN telomere length is highly similar to SM B cells and significantly shorter than naive and USM cells — independent confirmation of extensive prior division, orthogonal to the SHM argument (see Beckers2023 - Origins and Functions of DN B Cells, review, citing Colonna-Romano 2009).

  • Morphology matches memory, not naive. By FSC/SSC, DN cells of HD resemble USM and SM cells in size and granularity; both are significantly higher than naive B cells (see Beckers2023 - Origins and Functions of DN B Cells, review, citing Wu 2011).

  • DN cells expand after vaccination — antigen-driven, not merely degenerate. Increased DN frequencies follow influenza and tick-borne encephalitis virus vaccination, indicating antigen-driven maturation of DN cells on stimulation (see Beckers2023 - Origins and Functions of DN B Cells, review, citing Ruschil 2020).

  • Senescence/exhaustion signature in healthy donors. In young and aged HD, circulating DN cells show low anti-apoptotic Bcl2 and express SASP markers — TNF-α, IL-6, IL-8, the cell-cycle regulator p16^INK4, and inflammatory microRNAs miR-155, miR-16, miR-96 (see Beckers2023 - Origins and Functions of DN B Cells, review, citing Frasca 2017).

  • ★ The inhibitory-receptor phenotype splits by disease class — a phenotypic axis for “exhausted” vs. “activated” DN cells. DN and CD20^hi CD27⁻CD21^lo cells express multiple inhibitory receptors (FcRH3-5, CD22, CD85j) in HIV infection, malaria, anti-SARS-CoV-2 immunisation, and young/aged HD — but DN cells lacking inhibitory receptors are reported in SLE and Hashimoto’s thyroiditis. CD32b (FcγRIIb) is significantly decreased on DN cells in Hashimoto’s. The review’s synthesis: DN cells resemble exhausted cells in aging and chronic viral infection, but carry a higher activation state in autoimmunity (see Beckers2023 - Origins and Functions of DN B Cells, review, citing Moir 2008 / Weiss 2009 / Portugal 2015 / Castleman 2022 / Martorana 2014 for the inhibitory-receptor-positive settings, and Wei 2007 / Liu 2017 for the SLE and Hashimoto’s exception).

  • In normal aging, DN frequency correlates with age — and with cytotoxic CD4⁺CD28⁻ T cells. DN cells are increased in aged HD (>60 y) vs. young (<60 y) and correlate positively with age and with age-associated cytotoxic CD4⁺CD28⁻ T cell levels. This age correlation is the baseline against which the autoimmune diseases are read (see Beckers2023 - Origins and Functions of DN B Cells, review, own data + citing Colonna-Romano 2009).

  • ★ The age correlation is absent in SLE, pSS and MS — but present in axSpA. Unlike normal aging, DN frequency does not correlate with age in SLE, primary Sjögren’s, or MS, which the authors read as premature elevation / accelerated immune aging. In axial spondyloarthritis, by contrast, CD27⁻CD38^low CD21^low levels do correlate positively with age. Age-correlation is therefore not a universal property of pathological DN expansion (see Beckers2023 - Origins and Functions of DN B Cells, review, own MS data + citing Jenks 2018 for SLE and Wilbrink 2021 for pSS/axSpA).

  • A fourth, orthogonal classification: DN^low / DN^int / DN^hi by CD19 intensity + CXCR5. Szelinski et al. (2022) subdivide DN cells as DN^int (CD19^int CXCR5⁺), DN^hi (CD19^hi CXCR5⁻) and DN^low (CD19^low CXCR5⁻ — Beckers’ body text prints CXCR5⁺, but Table 1 of the same review and Szelinski’s own title say CXCR5⁻; the wiki reads the body text as a typo). DN^int and DN^hi share phenotype with DN1 and DN2 respectively. DN^low is a putatively new antigen-experienced subset, increased in SLE, that lacks CD11c yet shares the phenotype and transcriptome of plasmablasts — i.e. a candidate effector population invisible to CD11c-gated DN2 panels. DN^low + DN^hi are reported elevated in SLE, pSS, RA and COVID-19. Validation and mapping onto DN1-3 are outstanding (see Beckers2023 - Origins and Functions of DN B Cells, review, citing Szelinski 2022; see also Atypical B Cell Contradictions).

  • DN cells traffic to inflamed tissue. DN cells express CXCR3 (young HD) and CCR6 (elderly HD), with both in HIV infection; CXCR3⁺ DN frequencies are increased in SLE and axSpA. DN cells have been identified in inflamed RA synovial tissue and in MS cerebrospinal fluid (see Beckers2023 - Origins and Functions of DN B Cells, review, own MS/CSF data + citing Bulati 2014 / Moir 2008).

  • ⚠ IBD is the one condition where blood DN cells fall. DN cells are decreased in the circulation of inflammatory bowel disease patients but enriched in gut-associated lymphoid tissue — interpreted as recruitment out of blood into tissue. This is a caution for any blood-only DN measurement in a tissue-tropic disease (see Beckers2023 - Origins and Functions of DN B Cells, review, citing Carrasco 2019).

  • ⚠ Mouse “DN” and human “DN” are different cells defined by different markers — the shared acronym is a naming collision, not a homology. In humans DN means IgD⁻CD27⁻. In mice, “DN memory” means CD80⁻PDL2⁻ (or, in an alternative scheme, CD80⁻CD73⁻), with “DP memory” as CD80⁺PDL2⁺. Table 1 of the consensus Perspective carries the footnote: “‘DN’ in mice and ‘DN’ in humans refers to different markers and different B cell subsets.” Any mouse-to-human transfer of a “DN” result in this wiki must therefore be checked against which markers were actually used (see Eisenbarth2025 - A Roadmap for Defining Extrafollicular B Cell Responses, consensus Perspective, 12 authors, no primary data).

  • In mice, GC-independent responses generate both DN and DP memory, and the two have opposite recall fates. Both are long-lived. DP (CD80⁺PDL2⁺) memory preferentially differentiates into ASCs on secondary challenge; DN (CD80⁻PDL2⁻) memory is the subset most likely to re-enter a GC. Alum-adjuvanted GC responses generate almost exclusively DP memory. DP memory arising from GC-independent responses also divides more than DP memory of GC origin, and the two differ in gene expression and open chromatin — i.e. origin leaves a durable mark on cells of identical surface phenotype (see Eisenbarth2025 - A Roadmap for Defining Extrafollicular B Cell Responses, consensus Perspective, 12 authors, no primary data).

  • ★ [2026-08-27] PRIMARY DATA — DN cells dominate the B cell infiltrate of diseased end organs, and the increase is in total DN, not in any one subset. Multi-colour immunofluorescence across two diseases: IgG4-RD submandibular gland (n=10 vs n=7 chronic sialadenitis) — DN as % of tissue B cells ~35% vs ~16% (p<0.05), density ~255 vs ~40 cells/mm² (p<0.01); severe COVID-19 lung (n=6 vs n=6 non-COVID autopsy) — ~29% vs ~11% (p<0.05), ~16 vs ~2 cells/mm² (p<0.05); COVID-19 thoracic lymph node (n=6) — DN made up 18–66% of all CD19⁺ B cells. In IgG4-RD tissue, DN cells outnumbered IgD⁻CD27⁺ switched B cells in every individual, and also outnumbered plasmablasts. ⚠ The significance markers attach to the total-DN comparisons only — the subset-level panels (Figs. 5F, 5G, 6D, 6E) carry none, n=6–10 per arm, and p-values were not corrected for multiplicity (see Allard-Chamard2023 - DN3 B Cells Infiltrate Inflamed Tissues, multi-colour IF).

  • ★ [2026-08-27] PRIMARY DATA — DN2 is nearly absent from inflamed tissue, and this cuts against how the wiki has framed the DN compartment. In COVID-19 thoracic lymph nodes DN2 was ~7 cells/mm² against DN3’s ~400 — a ~fifty-fold gap; in IgG4-RD salivary gland DN2 was ~6/mm² and ~3% of the tissue DN pool. The authors state plainly that DN2 cells “are not abundant in COVID-19 lymph nodes and are relatively sparse in both IgG4-RD and COVID-19 end organs.” The subset on which the SLE extrafollicular case is built is not the one found in inflamed tissue — DN1 and DN3 are. Whether DN2 is a short-lived blood-transit state, is retained elsewhere, or simply loses CD11c detectability in FFPE is untested (see Allard-Chamard2023 - DN3 B Cells Infiltrate Inflamed Tissues, n=6 autopsy + n=10 SMG).

  • ★ [2026-08-27] PRIMARY DATA — tissue T-B conjugates are DN-dominated and essentially CD4-restricted. Cell-cell contacts quantified by cytoplasmic overlap (StrataQuest, 3-pixel ring from the DAPI nuclear mask) formed primarily between DN B cells and T cells, and between plasmablasts and T cells; conjugates with switched CD27⁺CD20⁺ memory B cells were rare (n=4). Almost all B–T interactions involved CD4⁺, not CD8⁺, T cells; the few DN–CD8⁺ conjugates came from a single patient with unusually high cell numbers. Confirmed in both COVID-19 lung/lymph node and IgG4-RD gland. This is the wiki’s first direct tissue-level evidence that DN cells are the B cell population engaging T cell help in situ (see Allard-Chamard2023 - DN3 B Cells Infiltrate Inflamed Tissues, n=4 tissue IF). See Extrafollicular T Cell Help.

  • [2026-08-27] PRIMARY DATA — the four DN subsets are transcriptomically distinct, and DN1/DN2 reproduce their lupus counterparts. Bulk RNA-seq of sorted DN1–DN4 from IgG4-RD blood (n=4, SMART-Seq2, GEO GSE220582): DN1 and DN2 transcriptomes broadly matched those described in SLE by Scharer2019 - Epigenetic Programming in SLE B Cells — cross-disease reproducibility of the DN1/DN2 split in a completely different disease context. DN3 alone carried a proliferation + unfolded-protein-response signature; DN4 was separated from DN1 by Notch and ubiquitination gene sets. DN2 and DN3 share a cytotoxic gene module (GZMA, GZMH, GZMB, GNLY, NKG7, KLRB1, KLRD1, KLRF1, FCGR3A, plus SLAMF7), with perforin generally low in DN3 (see Allard-Chamard2023 - DN3 B Cells Infiltrate Inflamed Tissues, n=4 bulk RNA-seq).

  • [2026-08-27] PRIMARY DATA — FcRL4 separates HIV DN cells from other disease DN cells in blood. FcRL4⁺ cells were ~15–18% of DN B cells in HIV (n=5) versus ~1% in healthy controls and in IgG4-RD (n=5 each), p<0.0001. The IgG4-RD DN distribution was also distinguishable from the lupus DN distribution, in which DN3 and DN4 are generally rare. ⚠ This contradicts a standing wiki claim — see Contradictions & Debates (see Allard-Chamard2023 - DN3 B Cells Infiltrate Inflamed Tissues, n=5 per group). See FcRH4.

  • [2026-08-27] PRIMARY DATA — whole-compartment shifts in IgG4-RD blood (n=38). As % of total B cells: DN increased (p<0.01), plasmablasts increased (p<0.05), unswitched memory / marginal zone decreased (p<0.01); total switched memory and naive unchanged. Within switched memory, classic CXCR5⁺ SWM fell and CXCR5⁻ “ABC-like” cells rose (both p<0.01); activated naive B cells rose (p<0.01). ⚠ The paper’s “ABC-like” gate is IgD⁻CD27⁺CXCR5⁻ and deliberately includes both CD11c⁺ and CD11c⁻ cells — it is CD27-positive and therefore does not overlap the DN compartment at all (see Allard-Chamard2023 - DN3 B Cells Infiltrate Inflamed Tissues, n=38). See Age-Associated B Cell, Activated Naive B Cell.

  • ★ [2026-08-29] DN expansion tracks organ involvement, not disease label. Across the lupus spectrum — primary chronic cutaneous lupus (CCLE+/SLE−), SLE with cutaneous disease (SLE+/CCLE+) and SLE without it (SLE+/CCLE−) — DN cells were expanded in all three groups, but highest in SLE without skin disease, and within SLE the presence of CCLE correlated with DN expansion of lower magnitude. The authors connect this to the DN2–lupus-nephritis association from Jenks2018 - DN2 B Cells and EF Pathway in SLE and to the reduced incidence of nephritis in SLE patients with discoid lesions. In every group the expansion was accounted for by DN2 and DN3 with reversal of the normal DN1 predominance — the same pattern as in SLE and severe COVID-19 (see Jenks2021 - B Cell Subset Composition in Cutaneous Lupus, n=207 patients + 46 healthy controls, cross-sectional, conventional flow). ⚠ Cross-sectional association within one cohort; not tested mechanistically.

  • [2026-08-29] Primary CCLE is bimodal for the DN phenotype, and that is a design warning. Unsupervised clustering on subset frequencies placed 42% of primary CCLE patients in the healthy-donor clusters (the Discussion says 48% — see the source page’s quarantined inconsistency) and the rest with SLE. The DN/effector phenotype was therefore a property of a patient stratum, not of the diagnosis. Any study comparing group means of DN frequency across clinical categories will dilute this kind of signal (see Jenks2021 - B Cell Subset Composition in Cutaneous Lupus, n=69 primary CCLE).

Proposed Origin and Relationship to Extrafollicular Response

Wei et al. propose that DN cells represent B cells that failed to complete a productive germinal centre reaction and instead differentiated via extrafollicular pathways. The reasoning is:

  1. CD27 is normally acquired via CD40–CD154-mediated B–T cognate interactions within the GC.
  2. DN cells show lower SHM rates than CD27⁺ cells, consistent with less extensive GC passage or GC-independent hypermutation.
  3. Murine studies demonstrate that SHM can occur outside GCs at GC-comparable rates (see William2002 - Extrafollicular Somatic Hypermutation in Autoimmune Mice).
  4. CD11c⁺ dendritic cells can activate extrafollicular B cells and induce CD40-independent class switching via BLyS-BAFF-R interactions.

This EF origin model directly links DN B cells to the concept of Extrafollicular Response and makes them the prototypical human EF memory B cell population. See Wei2007 - DN Memory B Cells in SLE for the full mechanistic argument.

Resolution by Jenks2018 — DN1 and DN2 are separate lineages: The DN1/DN2 subdivision resolves the origin debate. DN1 cells (CXCR5⁺, TCF7⁺) share a near-identical transcriptome with SWM (22 DEGs) and likely represent early switched memory precursors that have not yet acquired CD27 — a GC-derived population. DN2 cells (CXCR5⁻, T-bet⁺, ZEB2⁺, TCF7⁻) are extrafollicular effector cells with a distinct transcriptional programme. CD40L stimulation inhibits rNAV differentiation into aNAV and DN2 but does not affect DN1 generation, supporting separate pathway origin. The original Wei2007 “EF origin” hypothesis applies to DN2 cells specifically, not to the undivided DN compartment (see Jenks2018 - DN2 B Cells and EF Pathway in SLE).

Relationship to atypical/T-bet⁺ B cells: The later literature (post-2010) increasingly characterises a CD21⁻CD27⁻ or IgD⁻CD27⁻ population in acute infections as “atypical B cells” or “age-associated B cells (ABCs)” with T-bet expression, FcRL5⁺, and CD11c⁺ features. These populations substantially overlap with DN2 B cells as defined by Jenks2018. The DN2 phenotype (CXCR5⁻, CD11c⁺, T-bet⁺, FCRL4⁻, FCRL5⁺) provides the most precise current definition and resolves several prior ambiguities in the field. DN2 cells lack FCRL4 (distinguishing them from HIV exhausted memory cells) but retain intact BCR signalling (distinguishing them from malaria atypical memory cells). See DN2 B Cell for full characterisation.

⚠ The Jenks2018 “resolution” is a working model, not a settled result (Beckers2023). A 2023 review of the whole DN literature lays out three competing origin hypotheses and declines to choose between them:

  1. Premature exit from the GC reaction (proposed for DN1). DN1 cells express CXCR5; the number of cell divisions and Ig mutations in IgG⁺CD27⁻ DN cells resembles GC B cells (citing Berkowska 2011), while the mutation load stays below SM cells. Class-switched (IgA⁺/IgG⁺) CD27⁻ cells carry significantly more VH mutation than naive and USM cells but less than SM cells. On this reading DN1 is a CD27⁺-memory precursor caught early.
  2. Descent from SM cells via CD27 downregulation. AIRR sequencing finds only a 0.2–2.2% clonal overlap between DN and SM cells, with matched mutation load in the shared clones; DN1 and SM differ by just 22 differentially expressed genes. The proposed mechanism for CD27 loss is immunosenescence under chronic antigen stimulation — the “exhausted memory B cell” framing.
  3. GC-independent (extrafollicular) origin (proposed for DN2/DN3). The majority of DN and SM cells are clonally distinct, with different IgV(D)J family and gene usage; DN2 lacks CXCR5 and CD62L; DN2 shares transcriptome and expanded clones with activated naive B cells, and aNAV cells differentiate into DN2 in vitro under TLR7 + IFN-γ + IL-21.

Single-cell RNA velocity has been reported flowing in both directions — DN1 → SM (DN1 as precursor) and SM → DN1 (DN1 as progeny) — plus USM → DN2/DN3. Beckers’ own conclusion is that “conclusive evidence is still lacking… Some DN1 cells could be precursors of SM B cells, while others could be progeny of SM B cells.” One AIRR study went further, reading genealogical trees as pointing to DN cells as the progenitor of SM cells, and finding no difference in VH family usage or mutation type/location between class-switched DN and SM cells (see Beckers2023 - Origins and Functions of DN B Cells, review, own AIRR data — Fraussen 2019 — + citing Wu 2011 for the repertoire trees and Stewart 2021 for the velocity analyses). See Switched Memory B Cell and Single-Cell RNA Sequencing.

  • ★ The DN compartment is heterogeneous by direct phenotype, and the review says so in as many words. Comparing DN cells across RA, SLE, scleroderma and acute and chronic HIV, FcRL4 and FCRL5 are reciprocally expressed — FcRL4 high in HIV (~21.1%) and near-absent in SLE (~0.74%), FcRL5 the reverse. The stated conclusion: “This heterogeneity in expression patterns is indicative of multiple DN B cell populations, and can only be resolved by further marker subgating on DN B cells.” Table 1 accordingly gives three DN rows — DN1 (memory precursors), DN2 (extrafollicular ASC precursors) and an FcRL4⁺ atypical/tissue-based memory row — not two (see Sanz2019 - Consistent Classification of Human B Cell Populations, review — no original data), figure adapted from Jenks2018 - DN2 B Cells and EF Pathway in SLE).

  • Quantitative composition of the DN gate in expanded SLE patients. Within the IgD⁻CD27⁻ B_DN_ compartment of SLE patients with DN expansion, DN2 (T-bet^hi^CXCR5^neg^CD11c^hi^) accounted for 79% and DN1 (CXCR5⁺CD11c^lo^, T-bet^neg^) for 17% (see Zumaquero2019 - IFN-gamma Programs T-bet-hi B Cells for ASC Differentiation, n=16–18 SLE for phenotyping). DN2 but not DN1 uniformly expressed high T-bet, CD19 and FcRL5. ⚠ This is the CXCR5 × CD11c axis, not the CD21 × CD11c axis — note when comparing with sources that gate DN differently, and see this page’s DN3/DN4 sections where the axis choice changes which cells fall in which quadrant.

Contradictions & Debates

  • ★ Do DN B cells proliferate to TLR9/CpG? Four studies, four answers — the review calls it unresolved. The wiki has been carrying Wei2007’s positive CpG result as settled. Beckers2023 - Origins and Functions of DN B Cells tabulates the conflict: CpG alone gave no proliferation in young and elderly HD (Colonna-Romano 2009); the same group later found significant proliferation to CpG or anti-BCR+anti-CD40 in young but not elderly HD (Martorana 2014); a third study found CpG-driven proliferation at SM-cell levels (Wei 2007); and a fourth found no proliferation to anti-BCR+CpG+IL-4 in young or aged HD (Frasca 2019). Only triple stimulation (CpG+anti-BCR+anti-CD40) activated DN cells of both young and elderly HD. Beckers attributes the spread to differing proliferation markers, stimulation conditions and HD cohorts, and concludes that “the activation potential and responsiveness of DN B cells towards BCR and TLR signaling are still a topic of debate.” Age of the donor cohort is a candidate hidden variable in every one of these comparisons. (see TLR9, In Vitro B Cell Stimulation).

  • Unresponsive by activation marker, but signalling-competent by phospho-flow. DN cells show a decreased percentage of CD86⁺ activated cells after triple (CpG+anti-BCR+CD40L) or CD40L stimulation relative to total B cells in HD and MS — yet DN1-3 cells from HD, mild and severe COVID-19, and post-vaccination donors all maintain BCR signalling after IgG stimulation, with DN2 showing the highest CD69/CD86 and the largest BCR signalling capacity of the three subsets. Whether DN cells are hyporesponsive therefore depends on the readout (see Beckers2023 - Origins and Functions of DN B Cells, review, own data + citing Castleman 2022; Phospho-Flow Cytometry).

  • Disease context can restore DN responsiveness. MS DN B cells showed an increased ability to become activated after CD40L stimulation compared with HD DN cells — so the hyporesponsive phenotype is not fixed (see Beckers2023 - Origins and Functions of DN B Cells, review, own data).

  • ⚠ DN1 also differentiates into ASCs — the DN1-memory / DN2-effector dichotomy is softer than the wiki has assumed. GC-dependent DN1 cells differentiate into ASCs in vitro under the same TLR7 + BCR ligation + IFN-γ + IL-21 cocktail used to drive DN2→PB. Whether DN1’s ASC differentiation is TLR7- or BCR-dependent is explicitly stated as unresolved. This does not overturn the DN1/DN2 functional split — DN2 remains the population with the ASC transcriptional programme (IRF4⁺, Ets-1⁻, BACH2⁻) and shared clones with plasma cells — but it means “DN1 is memory, DN2 is effector” should be read as a difference in propensity, not in capability (see Beckers2023 - Origins and Functions of DN B Cells, review, citing Jenks 2018).

  • ⚠ The MS DN population is largely not DN2 — the SLE model may not generalise across diseases. Only a minority of DN cells from MS patients could be retraced to CD21⁻CD11c⁺ (DN2-like) cells, whereas DN2 constitutes the majority of expanded DN cells in SLE. The review concludes the role of DN cells in MS pathology “could differ from that in SLE.” Since the wiki’s mechanistic case for dengue is built on the SLE/COVID DN2 model, this is a live caution: an expanded DN compartment does not by itself imply an expanded DN2 compartment (see Beckers2023 - Origins and Functions of DN B Cells, review, own MS data).

  • Wirths & Lanzavecchia (2005, Eur J Immunol — cited but not yet ingested) identified a CD27⁻ PBL memory population using R123 extrusion, but their population was almost exclusively IgG⁺ (no IgM memory cells) and represented only ~1% of PBL B cells. Wei et al.’s DN cells include IgM and IgA subsets and represent ~5% — the discrepancy may reflect differences in isolation method, R123 threshold, or healthy donor selection. This potential definitional inconsistency has not been resolved.

  • Whether DN cells represent a developmental dead-end (failed GC entrants) or a bona fide lineage with distinct progenitors remains unresolved. The CpG-driven CD27 upregulation by proliferating DN cells suggests plasticity rather than a fixed fate.

  • CD27 absence in DN cells may not always indicate failure to enter GCs — CD27 can be downregulated upon stimulation with CD70 (on activated T cells), TLR ligands, and cytokines. Some CD27⁻ memory cells may have originally expressed CD27 (see Sanz2025 - Human Atypical B Cells Overview, review).

  • Whether DN2 cells in different disease contexts (SLE, dengue, COVID-19, malaria) represent identical or merely phenotypically similar populations remains unresolved. The Sanz2025 review emphasises that context determines function: naïve-derived DN2 in primary responses vs. potential memory DN2 in recall settings.

  • Alternative lineage reframing challenges the EF pre-plasmablast model outside SLE: Sutton2021 scRNA-seq data show that no atBC cluster upregulates PC maintenance genes (XBP1, IRF4, PRDM1), and PCs are detached from the pseudotime manifold — arguing against DN/atBC cells being obligate pre-plasmablasts in healthy or infection contexts. However, Sutton’s own Discussion reconciles this as context-dependent: in SLE, chronic TLR7 stimulation can drive atBCs toward PC fate, while in vaccination/infection they remain within an alternative memory lineage. This reframes the DN2→PB pathway as a pathological possibility rather than a default property (see Sutton2021 - Alternative Lineage B Cells in Vaccination and Infection, n=4, 10x Chromium + pseudotime).

  • COVID-19 validates the SLE EF pathway in infection — but pathogenesis mechanism unclear: Woodruff2020 shows that CoV-A patients have DN profiles (DN2:DN1 ratio, DN composition) statistically indistinguishable from active SLE. This validates the SLE-derived EF model in acute viral infection, but whether EF activation drives pathogenesis or simply correlates with severity remains unresolved (see Woodruff2020 - EF B Cell Responses in COVID-19).

  • Distinction from acN cells: During SLE flares, the circulating pool contains both DN memory B cells (IgD⁻CD27⁻) and a newly characterised activated naive (acN) population (IgD⁺CD27⁻, CD19^hi, MTG⁺, CD24⁻). These are distinct: acN cells retain IgD surface expression (not yet class-switched), while DN cells are IgD⁻. The Tipton2015 data show that acN cells — not pre-existing DN memory cells — are the primary precursor of circulating ASCs during SLE flares (see Tipton2015 - ASC Diversity and Origin in SLE). Jenks2018 subsequently showed that aNAV cells share a near-identical transcriptome and phenotype with DN2 cells and demonstrated the developmental link: aNAV → DN2 → plasmablast (see Jenks2018 - DN2 B Cells and EF Pathway in SLE).

  • Are DN B cells and ABCs “two sides of the same coin”? The opinion that anchors this debate answers partially, and context-dependently: the IgD⁻CD27⁻ ABC subset ≈ DN2, but ABC is a broader population (also CD27⁺/IgD⁺) and DN is broader on its non-DN2 subsets — so neither label contains the other. Even within their T-bet⁺CD11c⁺ overlap, ABCs are transcriptomically distinct from DN2 (Maul 2021). The wiki therefore keeps DN and ABC as related-but-non-identical (see Lamprinou2026 - ABCs and DN B Cells, opinion; Age-Associated B Cell; Atypical B Cell).

  • Three-subset vs four-subset DN taxonomy. Sanz2025 (and most wiki pages) use DN1/DN2/DN3; the Sachinidis/Garyfallos lineage adds DN4 (allergy-associated, CXCR5⁺). This is granularity/nomenclature drift, not a factual disagreement, but consumers of dengue data should be aware that CXCR5⁺ DN subsets (DN1, DN4) are systematically discarded by CXCR5⁻-focused EF gating.

  • Is the DN nomenclature itself worth keeping? The consensus Perspective recommends against terms built on “DN” and “DP” precisely because they name different cells in different species and rest on markers that may change over time with activation state. Its proposed replacements are process-based: DN1 → “memory GCB” or “memory non-GCB” as the evidence warrants, DN2 → “primary switched non-GCB” (see Eisenbarth2025 - A Roadmap for Defining Extrafollicular B Cell Responses, consensus Perspective, 12 authors, no primary data). The curator’s decision (2026-08-27) is to hold these as an annotation layer — recorded, not adopted — since DN1/DN2/DN3 is the vocabulary of the literature this wiki indexes, and renaming would sever searchability. The tension is real and is recorded rather than resolved.

  • ⚠★ [2026-08-27] Are peripheral-blood DN cells uniformly FcRH4-negative? Two primaries disagree. Wei2007 - DN Memory B Cells in SLE reports that FcRH4 “expression is absent from all peripheral blood B cell subsets” (n=29 healthy + n=36 SLE), and the wiki has used that to justify treating FcRH4 as a tissue-residency marker. Allard-Chamard2023 - DN3 B Cells Infiltrate Inflamed Tissues measures ~15–18% FcRL4⁺ within blood DN cells in HIV (n=5, p<0.0001 vs healthy and IgG4-RD). The likely reconciliation is disease context, not a flat contradiction — Wei studied healthy donors and SLE, neither of which Allard-Chamard finds FcRL4 in either (~1% in both healthy controls and IgG4-RD, consistent with Wei). HIV appears to be the exception, matching the separately reported FcRL4⁺ pro-inflammatory B cell subset in viraemic HIV. Practical consequence: FcRH4 negativity cannot be assumed for blood DN cells in a chronic viral infection, which is the relevant caution for any arboviral setting. Both n’s are small (n=5 per group in the HIV comparison).

  • ⚠★ [2026-08-27] DN4 is CXCR5⁺CD11c⁺ in the primary and CXCR5⁺CD11c⁻ in the wiki’s relay — see the boxed note in Overview. Unresolved and blocked by the PDF-only sourcing rule.

Atypical B Cell, Age-Associated B Cell, DN2 B Cell, DN3 B Cell, Early Memory B Cell, CD27, IgD, FcRH4, FCRL5, CD38, CD11c, CXCR5, T-bet, Memory B Cell, Extrafollicular Response, Germinal Center, Somatic Hypermutation, B220

Analysis: Why DN B Cells Matter - Disease Relevance and Infectious Disease Case — the corpus-wide justification case for this population, with every argument tiered by evidence provenance., GC-Independent Response

Sources

Graph View

Backlinks